{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"241"}],"title":"Negative"},{"measurements":[{"groupId":"OG000","value":"9"}],"title":"Pre-existing"},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Treatment-emergent Response"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"255"}],"units":"Participants"}],"description":"The ADA status of each participant was classified as one of the following:\n\n* Pre-existing - If the baseline sample is positive and all post baseline ADA titers are reported as less than 9-fold the baseline titer value\n* Negative - If all samples are found to be negative in the ADA assay\n* Treatment-emergent response","groups":[{"description":"Participants received cemiplimab monotherapy","id":"OG000","title":"Cemiplimab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The ADA analysis set (AAS) included all participants who received any cemiplimab and who had at least 1 post-dose ADA result.","reportingStatus":"POSTED","timeFrame":"Up to 73.5 months","title":"Number of Participants With Anti-Cemiplimab Antibodies (ADA)","type":"SECONDARY","unitOfMeasure":"Participants"}